Oblato, Inc. Report issue

For profit Phase 2
Founded: Princeton NJ United States (2015)

Organization Overview

First Clinical Trial
2015
NCT01672463
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Oblato, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

okn-007 (5 trials)

temozolomide (temodar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Oligodendroglioma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 2